Adenosine-induced ventricular arrhythmias in patients with supraventricular tachycardias

Adenosine triphosphate-induced life-threatening arrhythmia

A 68-year-old woman with idiopathic dilated cardiomyopathy presented with a wide QRS complex regular tachycardia five days after mitral valve replacement. Adenosine triphosphate (ATP) was administered to make the correct diagnosis; however, tachycardia eventually transitioned to ventricular fibrillation, which required cardioversion. Although ATP is considered a relatively safe drug, it can cause unexpected, life-threatening arrhythmias. Careful monitoring and preparation are advised during ATP administration in the event of a regular wide QRS complex tachycardia in patients with irritable conditions.

Learning objective

Adenosine triphosphate (ATP) is considered a safe drug that is often used to manage wide QRS complex tachycardia. Herein, we present a case of regular, wide QRS complex tachycardia in a patient who underwent mitral valve replacement. Tachycardia degenerated into ventricular fibrillation soon after ATP administration, probably because of sympathetic overdrive secondary to the ATP infusion. It is advisable to use ATP with caution, especially in irritable cases such as in the early post-cardiac surgery period.

Rare Paradoxical Response of Tachyarrhythmia to Adenosine Complicated by Novel ECG Artifact

Adenosine is widely used for the diagnosis and treatment of supraventricular tachyarrhythmia. We report a rare case of adenosine use associated with the development of 1:1 atrial flutter with aberrancy. The diagnosis was further complicated by a newly described ECG artifact associated with Wireless Acquisition Module (WAMTM) ECG acquisition mimicking rhythm irregularity.

Adenosine-induced ventricular fibrillation in a patient with supraventricular tachycardia

Adenosine is frequently used for paroxysmal supraventricular tachycardia (PSVT) treatment in the emergency department (ED). Atrial and ventricular pro-arrhythmic effects of adenosine were described in the literature, but ventricular fibrillation (VF) secondary to adenosine administration was rarely reported (with an incidence of < 1%). Reported herein is the first case of a 72-year-old female patient who developed VF hemodynamic collapse after an intravenous administration of adenosine for PSVT treatment. She had no known pre-excitation or accessory pathway, nor any underlying structural heart disease or prolonged QT syndrome. Raising awareness of this potential life-threatening pro-arrhythmic effect of adenosine is important, given its frequent use for PSVT treatment in the ED.

Part 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations

Note From the Writing Group: Throughout this article, the reader will notice combinations of superscripted letters and numbers (eg, “Family Presence During ResuscitationPeds-003”). These callouts are hyperlinked to evidence-based worksheets, which were used in the development of this article. An appendix of worksheets, applicable to this article, is located at the end of the text. The worksheets are available in PDF format and are open access.

Antiarrhythmic Drug Therapy of Supraventricular Tachycardia

Pharmacologic therapy is commonly used for the acute treatment and termination of paroxysmal supraventricular tachycardia (SVT) and continues to be an important long-term option for some patients. Drug choice depends on the correct diagnosis of the arrhythmia and an understanding of its mechanism. Pharmacologic agents commonly used in the acute and chronic treatment of SVT are reviewed along with their effect on the various types of SVT. Drugs that are well tolerated with minimal side effects are preferred over agents with perhaps more efficacy but higher risk of toxicity.

Ventricular tachycardia and ventricular fibrillation

Ventricular tachycardia and ventricular fibrillation are the most important causes of sudden cardiac death (SCD), particularly in those with structural heart disease and reduced left ventricular function. It is important to distinguish ventricular tachycardia from supraventricular tachycardia. A wide spectrum of ventricular arrhythmias exists, from those where the heart is structurally normal to those with structural heart disease. Each entity has a distinctive pathophysiology, treatment plan and prognostic outcome. Treatment modalities include simple beta-blockade to implantation of implantable cardiac defibrillator and ablative approaches. In general, those ventricular arrhythmias associated with a structurally normal heart are more benign than those associated with structural heart disease.